Logo de la Universitat de ValènciaLogo CSIC Logo del portal

Faça clic per a veure les últimes publicacions en Pubmed

 

2023

  • Álvarez-Rodríguez, B., Buceta, J., and Geller, R. (2023). Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3. Nat Commun 14, 6417. 10.1038/s41467-023-42144-2.
  • Caballos, I., Aranda, M.N., López‐Palacios, A., Pla, L., Santiago‐Felipe, S., Hernández‐Montoto, A., Tormo‐Mas, M.Á., Pemán, J., Gómez‐Ruiz, M.D., Calabuig, E., et al. (2023). Aptamer‐Capped Nanoporous Anodic Alumina for SARS‐CoV‐2 Spike Protein Detection. Adv Mater Technol 8. 10.1002/admt.202201913.
  • Camacho, J., Albert, E., Álvarez‐Rodríguez, B., Rusu, L., Zulaica, J., Moreno, A.R., Peiró, S., Geller, R., Navarro, D., and Giménez, E. (2023). A machine learning model for predicting serum neutralizing activity against Omicron SARS‐CoV‐2 BA.2 and BA.4/5 sublineages in the general population. J Med Virol 95. 10.1002/jmv.28739.
  • Bäuerl, C., Zulaica, J., Rusu, L., Moreno, A.R., Pérez-Cano, F.J., Lerin, C., Mena-Tudela, D., Aguilar-Camprubí, L., Parra-Llorca, A., Martínez-Costa, C., et al. (2023). Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers. iScience 26, 106802. 10.1016/j.isci.2023.106802.
  • Albert, E., Fernández‐Soto, D., Giménez, E., Casanovas, J.M., Zulaica, J., Álvarez‐Rodríguez, B., Rusu, L., Geller, R., Reyburn, H.T., and Navarro, D. (2023). Antibody‐dependent NK‐cell and neutralizing antibody responses against the Spike protein of Wuhan‐Hu‐1 and Omicron BA.1 SARS‐CoV‐2 variants in vaccinated experienced and vaccinated naïve individuals. J Med Virol 95. 10.1002/jmv.28900.
  • Serrat, J., Francés-Gómez, C., Becerro-Recio, D., González-Miguel, J., Geller, R., and Siles-Lucas, M. (2023). Antigens from the Helminth Fasciola hepatica Exert Antiviral Effects against SARS-CoV-2 In Vitro. Int J Mol Sci 24, 11597. 10.3390/ijms241411597.
  • Gargantilla, M., Francés, C., Adhav, A., Forcada-Nadal, A., Martínez-Gualda, B., Martí-Marí, O., López-Redondo, M.L., Melero, R., Marco-Marín, C., Gougeard, N., et al. (2023). C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein. J Med Chem 66. 10.1021/acs.jmedchem.3c00576.
  • Camacho, J., Albert, E., Zulaica, J., Álvarez‐Rodríguez, B., Rusu, L., Olea, B., Alcaraz, M.J., Geller, R., Giménez, E., and Navarro, D. (2023). A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti‐spike antibodies according to SARS‐CoV‐2 vaccination and infections status. J Med Virol 95. 10.1002/jmv.28397.
  • Camacho, J., Zulaica, J., Giménez, E., Rusu, L., Velandia-Álvarez, S., Albert, E., Peiró, S., Vanaclocha, H., Limón, R., Geller, R., et al. (2023). Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naïve individuals in the general population. Journal of Infection 86, 256–308. 10.1016/j.jinf.2022.12.029.
  • Panizo, N., Giménez, E., Albert, E., Zulaica, J., Rodríguez-Moreno, A., Rusu, L., Giménez-Civera, E., Puchades, M.J., D’Marco, L., Gandía-Salmerón, L., et al. (2022). SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients. Microorganisms 10, 2275. 10.3390/microorganisms10112275.
  • Camacho, J., Giménez, E., Albert, E., Zulaica, J., Álvarez‐Rodríguez, B., Torres, I., Rusu, L., Burgos, J.S., Peiró, S., Vanaclocha, H., et al. (2023). Cumulative incidence of SARS‐CoV‐2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant. J Med Virol 95. 10.1002/jmv.28284.

2022

  • Latorre V, Geller R. Identification of Cytoplasmic Chaperone Networks Relevant for Respiratory Syncytial Virus Replication. Front Microbiol. 2022;13. doi:10.3389/fmicb.2022.880394
  • Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodriguez P, et al. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. PLoS Pathog. 2022;18: e1010631-. Available: https://doi.org/10.1371/journal.ppat.1010631
  • Ruiz-Vega G, Soler M, Estevez MC, Ramirez-Priego P, Pazos MD, Noriega MA, et al. Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor. Sensors & Diagnostics. 2022. doi:10.1039/D2SD00082B
  • Torres I, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Burgos JS, et al. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection. J Med Virol. 2022. doi:10.1002/jmv.27867
  • Giménez E, Albert E, Zulaica J, Torres I, Rusu L, Moreno AR, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine. Clinical Infectious Diseases. 2022. doi:10.1093/cid/ciac223
  • Sánchez-Sendra B, Albert E, Zulaica J, Torres I, Giménez E, Botija P, et al. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci Rep. 2022;12: 3788. doi:10.1038/s41598-022-07849-2

2021

  • Ruiz-Rodriguez P, Francés-Gómez C, Chiner-Oms Á, López MG, Jiménez-Serrano S, Cancino-Muñoz I, et al. Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. mBio. 2021;12: e0231521. doi:10.1128/mBio.02315-21
  • Valdivia A, Torres I, Latorre V, Francés-Gómez C, Ferrer J, Forqué L, et al. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera. J Med Virol. 2021;93: 2301–2306. doi:10.1002/jmv.26697
  • Siles-Lucas M, González-Miguel J, Geller R, Sanjuan R, Pérez-Arévalo J, Martínez-Moreno Á. Potential Influence of Helminth Molecules on COVID-19 Pathology. Trends Parasitol. 2021;37: 11–14. doi:10.1016/j.pt.2020.10.002
  • Larrea L, Castro E, Navarro L, Vera B, Francés-Gómez C, Sánchez-Sendra B, et al. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after  pathogen reduction with methylene blue and visible light. Blood Transfus. 2021. doi:10.2450/2021.0136-21
  • Mattenberger F, Vila-Nistal M, Geller R. Increased RNA virus population diversity improves adaptability. Sci Rep. 2021 Mar 25;11(1):6824. doi: 10.1038/s41598-021-86375-z.
  • Guerreiro M, Aguilar-Gallardo C, Montoro J, Francés-Gómez C, Latorre V, Luna I, Planelles D, Carrasco MP, Gómez MD, González-Barberá EM, Aguado C, Sempere A, Solves P, Gómez-Seguí I, Balaguer-Rosello A, Louro A, Perla A, Larrea L, Sanz J, Arbona C, de la Rubia J, Geller R, Sanz MÁ, Sanz G, Luis Piñana J. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients? Transpl Infect Dis. 2021 Mar 17:e13602. doi: 10.1111/tid.13602.
  • Mattenberger F, Latorre V, Tirosh O, Stern A, Geller R. Globally defining the effects of mutations in a picornavirus capsid. Elife. 2021 Jan 12;10:e64256. doi: 10.7554/eLife.64256.
  • Valdivia A, Torres I, Latorre V, Francés-Gómez C, Albert E, Gozalbo-Rovira R, Alcaraz MJ, Buesa J, Rodríguez-Díaz J, Geller R, Navarro D. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021 Jan 6:1–10.

2020

  • Valdivia A, Torres I, Latorre V, Francés-Gómez C, Ferrer J, Forqué L, Costa R, de la Asunción CS, Huntley D, Gozalbo-Rovira R, Buesa J, Giménez E, Rodríguez-Díaz J, Geller R, Navarro D. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera. J Med Virol. 2020 Nov 25:10.
  • Siles-Lucas M, González-Miguel J, Geller R, Sanjuan R, Pérez-Arévalo J, Martínez-Moreno Á. Potential Influence of Helminth Molecules on COVID-19 Pathology. Trends Parasitol. 2021 Jan;37(1):11-14. doi:10.1016/j.pt.2020.10.002. Epub 2020 Oct 15.
  • Gozalbo-Rovira R, Gimenez E, Latorre V, Francés-Gómez C, Albert E, Buesa J, Marina A, Blasco ML, Signes-Costa J, Rodríguez-Díaz J, Geller R, Navarro D. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J Clin Virol. 2020 Oct;131:104611.

2019

  • Bou JV, Geller R, Sanjuán R. Membrane-Associated Enteroviruses Undergo Intercellular Transmission as Pools of Sibling Viral Genomes. Cell Rep. 2019 Oct 15;29(3):714-723.

2018

  • Latorre V*, Mattenberger F*, Geller R. Chaperoning the Mononegavirales: Current Knowledge and Future Directions. Viruses 2018, 10(12), 699
  • Geller R*, Pechmann S*, Acevedo A, Andino R, Frdyman J. Hsp90 shapes protein and RNA evolution to balance trade-offs between protein stability and aggregation. Nature Communications

2017

  • Geller R*, Pechmann S*, Acevedo A, Andino R, Frdyman J. Hsp90 dictates viral sequence space by balancing the evolutionary tradeoffs between protein stability, aggregation and translation rate. BioRxiv

2016

  • Geller R, Estada U, Peris JB, Andreu I, Bou JV, Garijo R, Cuevas JM, Sabariegos R, Mas A, Sanjuán R. The hepatitis C virus genome exhibits highly heterogeneous mutation rates. Nat Microbio. 2016 Apr 18

2015

  • Combe M, Garijo R, Geller R, Cuevas JM, Sanjuán R. Single-Cell Analysis of RNA Virus Infection Identifies Multiple Genetically Diverse Viral Genomes within Single Infectious Units. Cell Host Microbe. 2015 Oct 14;18(4):424-32
  • Geller R*, Domingo-Calap P*, Cuevas JM*, Rossolillo P, Negroni M, Sanjuán R. The external domains of the HIV-1 envelope are a mutational cold spot. Nat Commun. 2015 Oct 9;6:8571. *Shared first authors
  • Cuevas JM*, Geller R*, Garijo R, López-Aldeguer J, Sanjuán R. Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol. 2015 Sep 16;13(9):e1002252. *Shared first authors and highlighted in PLoS Biol

2013

  • Geller R, Andino R, Frydman J. Hsp90 Inhibitors Exhibit Resistance-Free Antiviral Activity against Respiratory Syncytial Virus. PLoS ONE. 2013 Feb 8(2); e56762

2012

  • Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, Chiosis G, Massoud TF, Paulmurugan R, Gambhir SS. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. PNAS. 2012 Sep 11;109(37):E2476-85

2011

  • Geller R, Taguwa S, Frydman J. (2011) Broad action of Hsp90 as a host chaperone required for viral replication. Biochim Biophys Acta. 2012 Mar;1823(3):698-706

2007

  • Geller R, Vignuzzi M, Andino R, Frydman J. (2007) Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21 (2):195-205

2006

  • Tam S, Geller R, Spiess C, Frydman J. (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol. 8 (10):1155-62

2002

  • Khakoo SI, Geller R, Shin S, Jenkins JA, Parham P. (2002) The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J Exp Med. 196 (7):911-21
  • Geller R, Adams EJ, Guethlein LA, Little AM, Madrigal JA, Parham P. (2002) Linkage of Patr-AL to Patr-A and- B in the major histocompatibility complex of the common chimpanzee (Pan troglodytes). Immunogenetics 54 (3):212-5

Segueix-nos: Twitter Viral Biology